TARGET AUDIENCE
This program is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of urothelial bladder carcinoma.

LEARNING OBJECTIVES

• Identify available clinical trial data supporting the FDA approvals of various immune checkpoint inhibitors for the treatment of urothelial bladder carcinoma (UBC) to determine the current utility of these agents in clinical practice.
• Consider the recent FDA approval of pembrolizumab for high-risk non-muscle-invasive UBC that is unresponsive to BCG, and determine how this agent can be appropriately integrated into clinical care.
• Evaluate available and emerging data with anti-PD-1/PD-L1 antibodies as neoadjuvant or adjuvant therapy for muscle-invasive bladder cancer, and refer eligible patients for appropriate trial participation.
• Evaluate available clinical trial data with anti-PD-1/PD-L1 antibodies as maintenance therapy after first-line chemotherapy for patients with previously untreated metastatic UBC, and consider the role of this approach in routine practice.
• Appraise available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents for UBC, and counsel appropriately selected patients about participation in active research protocols.
• Recall the mechanism of action of and recent data with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.

ACCREDITATION STATEMENTS
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Petros Grivas, MD, PhD
Associate Professor, Department of Medicine, Division of Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Advisory Committee: Merck, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Mirati Therapeutics, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Bavarian Nordic, Bristol-Myers Squibb Company, Clovis Oncology, Debiopharm Group, Immunomedics Inc, Kure It Cancer Research, Merck, Pfizer Inc, QED Therapeutics; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas and Seattle Genetics and Merck.

Release date: September 2020
Expiration date: September 2021